Showing 1671-1680 of 7783 results for "".
DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)AK Burden and Progression Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-burden-and-progression-risk/20134/Individuals with chronic sun damage are at higher risk of developing AK lesions. It is therefore essential that dermatologists emphasize early sun protection recommendations and address progression risks of AK with their patients. Faced with increasing burden of skin cancers, Joel L. Cohen, MD and AEstrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.The Roots of Dermatology
https://practicaldermatology.com/topics/practice-management/the-roots-of-dermatology/18355/The roots of dermatology run deep. The specialty formed in Europe, but Americans soon took a leading role in shaping the future of the field. This first of four episodes explores the early days of the specialty and takes stock of dermatology today.Clinical Conversations: MOA of JAK Inhibitors in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology/20096/JAK inhibitors have a range of potential applications in clinical dermatology. In the first video of this series, Brad Glick, DO and Raj Chovatiya, MD explain the mechanism of action of JAK inhibitors and explain how they may be used topically or systemically to treat skin diseases like atopic dermaChallenging Cases
https://practicaldermatology.com/conferences/maui-derm-2022/challenging-cases/20054/Seemal R. Desai, MD was part of the Challenging Cases session on everything from new infectious diseases to challenging surgical and aesthetic complications. He says dermatologists play an important role in saving and transforming patients' lives.An Update on Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/an-update-on-neuromodulators-and-fillers/19983/Suneel Chilukuri, MD discusses daxibotulinumtoxinA and its potential for longer lasting results. He also reviews newly available fillers and specific options for various areas of the face. Plus, he talks about low-cost options and how he’s using devices like SkinPen.Managing Patients with Atypical Nevi and Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-patients-with-atypical-nevi-and-melanoma/19982/Monitoring patients with several atypical nevi who are at high risk for melanoma is very challenging. Steven Q. Wang, MD offers tips for improving diagnostic accuracy and discusses the role of dermoscopy in detecting melanoma as well as non-melanoma skin cancers at much earlier rates.Nailed It: Foods for Hair and Nails
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/nailed-it-foods-for-hair-and-nails/19932/Zoe Draelos, MD is nuts about natural sources of nutrition and has some berry good news for those interested in alternative to supplements for the hair and nails. Hint: Not everyone needs supplements, she says.DermWireTV: Candela + Merz Aesthetics Partnership, COVID-19 Vaccines & Fillers, Almirall's Klisyri, MetSyn & PsO
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-candela-merz-aesthetics-partnership-covid-19-vaccines-and-fillers-almiralls-klisyri-metsyn-and-pso/19893/Klisyri® (tirbanibulin) ointment 1% from Almirall will be available for treatment of AKs by the end of this quarter; Ayman Grada, MD discusses. Are patients who have received dermal filler injections at risk for developing reactions to the COVID-19 vaccine? Joel L. Cohen, MD and Doris Day, MD weigh